

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-8. (Canceled)

9. (Currently Amended) A method for producing human Tr1-like regulatory cells, which method comprises the steps of:

(a) separating CD4<sup>+</sup> CD25<sup>+</sup> T cells from CD4<sup>+</sup> CD25<sup>-</sup> T cells; and

(b) anergizing energizing CD4<sup>+</sup> CD25<sup>-</sup> T cells by contacting the CD4<sup>+</sup> CD25<sup>-</sup> T cells with CD4<sup>+</sup> CD25<sup>-</sup> T cells an anergic state inducing agent *ex vivo* or *in vivo*.

10. (Canceled)

11. (Currently Amended) The method of claim ~~10~~ 9, wherein ~~the anergic state inducing agent comprises CD4<sup>+</sup> CD25<sup>+</sup> T cells and~~ step (b) of said method comprises co-culturing the CD4<sup>+</sup> CD25<sup>-</sup> T cells with CD4<sup>+</sup> CD25<sup>+</sup> T cells.

12.-28. (Canceled)

29. (Previously Presented) The method of claim 9, wherein said Tr1-like regulatory cells produce IL-10.

USSN 10/618,134

4

Amendment Under 37 CFR § 1.111 filed October 20, 2006

30. (Currently Amended) The method of claim 29, wherein said Tr1-like regulatory cells ~~inhibit~~ suppress the proliferation of syngeneic CD4<sup>+</sup> T cells.

31. (New) A method of suppressing the proliferation of CD4<sup>+</sup> T cells *ex vivo* or *in vivo* comprising introducing to a composition comprising said CD4<sup>+</sup> T cells the Tr-1 like regulatory cells produced according to the method of claim 9, and achieving a suppression in the proliferation of said CD4<sup>+</sup> T cells.

32. (New) The method of claim 31, wherein said Tr-1 like regulatory cells are produced according to the method of claim 9, wherein step (b) of said method of claim 9 comprises co-culturing the CD4<sup>+</sup> CD25<sup>-</sup> cells with CD4<sup>+</sup> CD25<sup>+</sup> cells *ex vivo*.

33. (New) The method of claim 31, wherein said Tr1-like regulatory cells produce IL-10.

34. (New) The method of claim 33, wherein said Tr1-like regulatory cells suppress the proliferation of syngeneic CD4<sup>+</sup> T cells.

**CONDITIONAL PETITION FOR EXTENSION OF TIME**

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully request that this be considered a petition therefor. The Commissioner is authorized to charge any fee(s) due in this connection to Deposit Account No. 14-1263.

**ADDITIONAL FEE**

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

USSN 10/618,134

6

Amendment Under 37 CFR § 1.111 filed October 20, 2006